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OBJECTIVES: Post-transplant patients have high risk of re-hospitalization, incurring 
relevant costs. The aim of this study is to analyze causes, resource use and costs of 
re-hospitalizations in a cohort of renal transplanted patients. METHODS: A longitu-
dinal analysis of a government administrative database (Inpatient Information 
System—SIH/DATASUS) was performed from January 2004 to July 2009. The study 
cohort was all patients who had undergone kidney transplant at 7 of the main trans-
plant hospitals in Brazil, in 2004. All patients were followed until July 2009. Demo-
graphic data (sex, age, type of donor), length of re-hospitalization, resource use and 
associated costs (in 2004 USD) were collected. RESULTS: A total of 1030 patients 
were eligible for the analysis. Mean age was 38.7 ± 14.5 years, 57.6% were male 
recipients and 49.6% of transplant procedures were from living donors. During the 
study period 2,168 hospitalizations occurred in 643 patients (62%), with a total cost 
of US$ 1,568,956. Most frequent causes of re-hospitalization were post-transplant 
surgical and clinical complications (40.1%) and graft rejection episodes (32.4%), 
accounting together for 76.9% (US$ 1,207,406) of total expenses. Hospital services 
(ICU/Ward days, operation room, equipments, etc) represent the most signiﬁcant part 
of re-hospitalization costs (40.9%), followed by diagnostic/laboratory exams (24.2%), 
medicines (13.6%) and health professional fees (11.0%). Re-hospitalizations were 
concentrated in the ﬁrst (39.6%) and second (24.0%) years following transplant, 
stabilizing in the fourth and ﬁfth years around 9% (200 hospitalizations/year). Patients 
receiving grafts from deceased donors accounted for 68.4% of total costs, and average 
costs per re-hospitalization were statistically different between patients receiving grafts 
from deceased (US$ 778 ± 1,181) relative to living donors (US$ 632 ± 973) (p < 0.01). 
CONCLUSIONS: The majority of patients who underwent kidney transplant in 2004 
were re-hospitalized at least once until July 2009. Costs associated with these re-
hospitalizations were concentrated in the ﬁrst year post-transplant and in cadaveric 
renal transplant recipients.
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OBJECTIVES: Graft rejection episodes are important causes of hospitalization in 
post-kidney transplant patients. The aim of this study is to analyze the incidence of 
rejection episodes (REs) requiring hospitalization after renal transplant, associated 
resource use and costs for the Brazilian Public Health System. METHODS: This is a 
longitudinal study combining data from two government databases (Outpatient and 
Inpatient Information Systems—SIA/DATASUS and SIH/DATASUS) connected by 
deterministic linkage. Diagnosis of REs was done by International Classiﬁcation of 
Diseases (ICD-10) indicated on hospitalization. Kidney transplant patients from 7 
hospitals in Brazil in 2004 with at least one additional database record were followed 
for 60 months post-transplant. Duration of hospitalization, resource use and costs 
converted to 2004 USD of all REs were collected. Kaplan-Meier curves for the ﬁrst 
episode categorized by type of donor were calculated. RESULTS: From 1044 kidney 
transplant patients recorded in the database, 797 (410 deceased and 387 living) were 
eligible to the analysis. Proportion of patients that have not experienced any RE at 
12, 24, and 60 months were 73.2%; 69.6%; and 60.1% in the living group and 
72.1%; 70.0% and 66.0% in the deceased group. Kaplan-Meier curves, average length 
of stay (10.1 ± 8.2 days in the living group and 8.9 ± 8.5 days in the deceased group) 
and costs (US$715 ± 874 in the living group and US$651 ± 1,012 in the deceased 
group) of REs hospitalizations were not statistically different (p > 0.05). Total hospi-
talization costs were US$480,585. Hospital services (ICU/Ward days, operation room, 
equipments, etc) represent the most signiﬁcant portion of costs (43.1%), followed by 
diagnostic/laboratory tests (26.1%). Among transplant-related medications, tacroli-
mus, OKT3 and basiliximab accounted, respectively, for 4.4%, 2.2% and 1.1% of 
total expenses. CONCLUSIONS: A total of 73% of kidney transplanted patients did 
not have REs in the ﬁrst year post-transplant. Type of donor does not seem to inﬂuence 
occurrence, costs or duration of hospitalization.
URINARY/KIDNEY DISORDERS – Patient-Reported Outcomes Studies
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OBJECTIVES: Given recent safety as well as cost concerns, an evidence-based guide-
line for erythropoiesis stimulating agents (ESA) in chronic kidney disease (CKD) was 
developed across a seven-hospital system. The purpose of this analysis was to evaluate 
adherence to the guideline. Speciﬁc objectives were to assess: whether 1) optimal 
hemoglobin levels (10–12 g/dL) were achieved, 2) ferritin or transferrin saturation 
(TSAT) was measured; and 3) iron therapy was administered, when appropriate. 
METHODS: The Research Patient Data Registry, a repository comprised of over four 
million patients and 900 million inpatient and outpatient encounters, diagnoses, 
medications, laboratory tests and results, and other medical care served as the data 
source. Data were available for three hospitals, two academic medical centers and a 
community teaching hospital. Patients were eligible for inclusion if they had a diag-
nosis of CKD based on ICD-9 diagnosis code and received at least two doses of ESA 
within three months. The analysis timeframe was November 2007 to April 2008. 
RESULTS: During the 6-month period, 344 eligible patients were identiﬁed. Of these, 
54% achieved target hemoglobin levels within three months of therapy initiation. 
Approximately 4% did not have hemoglobin measured within three months. In the 
remaining patients, the hemoglobin level was less than 10 g/dL or more than 12 g/dL 
in 17% and 26% of patients, respectively. In 15% of patients neither ferritin nor 
TSAT were assessed. Among those with a ferritin < 100 ng/mL, 9% did not receive 
iron supplementation. TSAT was recorded only in one patient. CONCLUSIONS: 
Approximately half of the patients achieved target hemoglobin levels, highlighting 
the difﬁculty in maintaining target hemoglobin. These data suggest that adherence to 
this guideline can be improved in hemoglobin and iron monitoring and with iron 
supplementation.
URINARY/KIDNEY DISORDERS – Health Care Use & Policy Studies
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In 2011, a new prospective payment system will be instituted for Medicare payments 
for dialysis. CMS analyses revealed that dialysis payments differ signiﬁcantly by race, 
yet CMS has not proposed including a racial case mix adjuster (CMA). Initial analyses 
showed that the proposed payment system without a racial CMA produced signiﬁcant 
underpayment in dialysis units serving large numbers of black patients. OBJECTIVES: 
Model the impact of adding a racial case mix adjuster on dialysis reimbursement to 
clinics serving black patients, including a geospatial mapping to understand regional 
impact. METHODS: We used the racial case mix weights reported by CMS (though 
not included as a CMA), as well as the projected payments under the current and 
proposed payment systems. We used updated census data on race on the county level 
for a national analysis, and actual race for analysis of only DaVita clinics. We calcu-
lated clinic-level change in reimbursement using race CMA weights, then lowered the 
base payment rate to offset the incremental costs associated with the race CMA. We 
then use geomapping to plot percentage change due to race CMA, and overall change 
in proposed payment, and differential between current payment and proposed 
payment with and without the racial CMA. RESULTS: Among the 4276 dialysis 
clinics analyzed, the addition of the race CMA increased payment in 1140 clinics and 
decreased payments in 1206 clinics; it increased payment by ≥2% in 292 clinics and 
decreased payment by ≥2% in 172 clinics. Without the race CMA, payment reductions 
of ≥ 10% were disproportionately seen in areas in the southeast and in large cities 
with high percentages of blacks. This was ameliorated by the addition of the race case 
mix adjuster. CONCLUSIONS: CMS should include a race CMA in the prospective 
payment system for dialysis.
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CASE MIX ADJUSTMENT: THE CONSEQUENCES OF DIVERGENCE IN 
ACCESS TO DATA
Mayne T, Burgess M, Weldon J
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The proposed Medicare prospective payment system for dialysis includes 18 case mix 
adjusters, 17 of which only increase payment. CMS calculated these adjusters using 
several data sources, including Medicare paid claims, and reduced the base payment 
22% to offset the associated incremental costs. OBJECTIVES: Determine the ability 
of a large dialysis organization to detect CMAs using all available data sources, and 
calculate the ﬁnancial impact of differences in CMAs ascertained by unit data, versus 
those reported by CMS. METHODS: Four dialysis units were randomly selected in 
each of 20 geographic regions. CMAs were ascertained via chart reviews, electronic 
medical records, hospital discharge summaries, paper charts, health care professional 
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notes, and discussions with on-site health care professionals. RESULTS: The ﬁnal 
sample included 100 clinics, with an average of 73.4 patients per unit. CMS provided 
estimated CMAs for 89 of these units. In 75 of 89 clinics, the case mix adjuster 
detected in the study was lower than that ascertained by CMS (mean difference = 
0.09). In 14 units, the CMA was higher than reported by CMS (mean difference = 
0.04). The average CMA for the 89 units was 1.21 versus 1.28 reported by CMS for 
these same units, with uneven geographic distribution on the difference. The inability 
to replicate CMS CMAs would result in a 7% decrease in payment, with a differential 
from CMS projected payments of > $350 million over a 4 year period. CONCLU-
SIONS: Without access to Medicare claims data, we were unable to replicate CMS 
CMAs, representing the potential for signiﬁcant underpayment for dialysis units under 
the proposed prospective payment system.
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BACKGROUND In 2011, a new prospective payment system will be instituted for 
Medicare payments for dialysis. Payments will be calculated per session. It is unclear 
how long-acting medications will fare under this new system, i.e., if patients are 
administered a monthly medication and then miss subsequent sessions, how will this 
impact revenue? OBJECTIVES: Model reimbursement for one long-acting drug under 
the proposed bundled payment system from the provider perspective. METHODS: 
We assumed that there would be one set of case mix adjusters (CMAs) and outlier 
payment for all currently separately billables; that monthly drugs are truly adminis-
tered only once per month; and that all payments are made in full, i.e., all 20% co-pays 
are made in full. We included 3 levels of drug utilization (for one drug) and 3 levels 
of other resource utilization, each ranging from 33% below to 33% above the current 
mean reported by CMS. We included 4 levels of rebates ranging from 0% to 50%. 
We examined 16 different CMAs, ranging from 0.6 to 3.6 in increments of 0.2. We 
varied the number of dialysis sessions in a month from 1 to 13. This 3 × 3 × 4 × 16 
× 13 matrix produced 7488 solutions. RESULTS: The model showed providers will 
incur losses when a patient receives a full drug dose in 1 session and misses all sub-
sequent sessions, unless manufacturers provide signiﬁcant rebates/price reductions. 
Losses occur even at 50% discounts when CMAs fall below 0.80. Greatest losses do 
not always occur when there is only 1 session in a month, but can occur at 2 to 7 
sessions (J-shaped curve). CONCLUSIONS: Losses on long-acting medications will 
occur, but can be mitigated and in some cases eliminated through manufacturer pricing 
discounts. However, the relationship between component costs, CMA and session 
number are non-linear.
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OBJECTIVES: This study evaluated dosing trends and hemoglobin levels over time in 
patients with chronic kidney disease (CKD) not on dialysis receiving epoetin alfa 
(EPO) or darbepoetin alfa (DARB), 2 erythropoiesis-stimulating agents (ESAs). 
METHODS: An analysis of medical claims between July 2000 and March 2009 from 
the Ingenix IMPACT database was conducted. Patients ³18 years, newly initiated on 
ESAs, with ³1 claim for CKD were included. Patients diagnosed with cancer, receiving 
chemotherapy or dialysis, or receiving both agents were excluded. Average weekly 
ESA dose, weighted by the treatment duration, was calculated and reported by semes-
ter to evaluate trends over time. For the subset of patients with laboratory data, 
semi-annual mean of baseline and achieved hemoglobin levels were assessed over time. 
RESULTS: A total of 4,182 ESA-treated patients were identiﬁed (EPO 2684; DARB 
1,498). Mean age was 64.2 and 63.2 in EPO and DARB groups, respectively, whereas 
proportion of women was 51% and 55%. The mean weekly dose was relatively stable 
for both ESAs over time (EPO: mean: 10,652 units; median: 10,623 units; 25th–75th 
percentiles: 9,872- 11,609 units; DARB: mean: 41 mcg; median: 42 mcg; 25th–75th 
percentiles: 38–43 mcg); however, a slight decreasing trend was observed in more 
recent years (2006–2008). Analysis of laboratory results revealed a declining trend in 
mean baseline hemoglobin over time (10.5 g/dL in 2003S1 vs. 10.1 g/dL in 2008S2) 
consistent with recent treatment guidelines. A decreasing trend was also observed in 
mean achieved hemoglobin during the treatment episode (11.9 g/dL in 2003S1 vs. 
10.9 g/dL in 2008S2). Furthermore, the proportion of patients with achieved hemo-
globin >12 g/dL decreased from 41% before April 2006 to 23% in April 2007, after 
the KDOQI guidelines changed. CONCLUSIONS: This analysis of data from CKD 
patients not on dialysis reported relatively stable ESA dosing trends and decreasing 
trend in hemoglobin levels during the study period.
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OBJECTIVES: To compare the utilization of epoetin alfa (EPO) and darbepoetin alfa 
(DARB), 2 erythropoiesis-stimulating agents (ESAs), in chronic kidney disease (CKD) 
patients not receiving dialysis before and after the National Kidney Foundation/Kidney 
Disease Outcomes Quality Initiative (KDOQI) Anemia Treatment Guideline changes 
in March 2007. METHODS: An analysis of medical claims from Ingenix IMPACT 
(2006–2008) and Medicare 5% (2006–2007) databases was conducted. Patients ≥18 
years, newly initiated on ESAs, with ≥1 claim for CKD were included. Patients diag-
nosed with cancer, receiving chemotherapy or dialysis, or receiving both agents were 
excluded. Patients initiating ESA prior to March 31, 2007 were classiﬁed into the 
pre-guideline changes group and compared with patients initiating ESA after March 
31, 2007 using the same time window prior and after KDOQI guideline changes. Dose 
per injection and cumulative dose evaluated up to 16 weeks after treatment initiation 
were compared. RESULTS: A total 3427 patients were identiﬁed from both data 
sources. Following guideline changes, a lower number of patients initiated ESAs 
changes in the IMPACT database (1,059 pre- vs. 518 post-guideline changes) while 
the number of ESA-treated patient was more stable in the Medicare database (875 
pre- vs. 975 post-guideline change). Among ESA-treated patients, the mean number 
of injections per patient decreased after the KDOQI guideline changes (pre- versus 
post-guideline changes: IMPACT—EPO: 4.0 vs. 3.8; DARB: 2.9 vs. 3.1; Medicare—
EPO: 5.4 vs. 5.1; DARB: 4.9 vs. 4.6). Mean cumulative dose administered per patient 
also decreased post-KDOQI guideline changes [IMPACT—EPO Units: 95,147 vs. 
86,898 (9% decrease) for pre- versus post-guideline changes, DARB mcg: 374 vs. 340 
(9% decrease); Medicare—EPO Units: 104,739 vs. 103,265 (15% decrease), DARB 
mcg: 557 vs. 520 (4% decrease)]. CONCLUSIONS: This observational study suggests 
that the recent KDOQI guideline changes impacted the ESA utilization patterns in 
CKD patients not receiving dialysis. A trend toward decreased ESA utilization was 
observed.
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EFFECTIVENESS RESEARCH
Seidenfeld JD1, Sonnad S1, Gruman J2
1Center for Medical Technology Policy, Baltimore, MD, USA, 2Center for Advancing Health, 
Washington, DC, USA
OBJECTIVES: Current efforts to inﬂuence health care using comparative effectiveness 
research (CER) often miss the opportunity to incorporate patient and consumer per-
spectives. The Center for Medical Technology Policy (CMTP) seeks to generate evi-
dence for decision-makers and recognizes the importance of including patients and 
consumers as fellow decision-makers. This paper reports on the formation of and 
recommendations from a Patient and Consumer Advisory Committee (PCAC) for 
CMTP. METHODS: Following a literature review on consumer advocacy in health 
and interviews with experts regarding appropriate structure and training for effective 
patient and consumer engagement in CER, CMTP convened a workgroup of consumer 
and patient advocates to review practices and create a set of recommendations for 
strengthening the patient and consumer voice in CMTP’s prioritization of technologies 
and development of guidelines for CER study designs. RESULTS: The workgroup’s 
key recommendations for technology prioritization include 1) how and when to solicit 
input on technology topics from patient/consumer groups; 2) the role of patients/
consumers in setting priorities that reﬂect public values; 3) the information require-
ments of patients / consumers to serve as effective public representatives; and 4) the 
characteristics of patients/consumers that would contribute a broad perspective. For 
the development of study design guidelines, 1) gather patient/consumer information 
preferences via semi-structured interviews; 2) address patient/consumer identiﬁed out-
comes; 3) consider having advocates who are also subject-matter experts review and 
comment on summaries from stakeholder meetings in addition to the public represen-
tatives who directly participate; and 4) consult with patient/consumer advocates about 
the suitability of disseminating project ﬁndings. CONCLUSIONS: As CER has 
expanded, a clear need has emerged for guidance on engaging public representatives 
in this area. There is a risk that the public’s voice will be lost in the CER enterprise 
unless action is taken to champion and bring it to the forefront of the discussion.
